People · Operator

Michael James Bigham

Named in public records as an officer, director or promoter · active 2011–2011 · Pharmaceuticals

1
Companies
2
Filings
$45.0M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Supernus Pharmaceuticals IncPharmaceuticalsSeries B$45.0M$1.0B2011
Operator network

Michael James Bigham at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

John M. Siebert · 4 companies · 1 sharedJohn M. SiebertM. James Barrett, Ph.D. · 3 companies · 1 sharedM. James Barrett,…Charles W. Newhall III · 2 companies · 1 sharedCharles W. Newhal…Frederick M. Hudson · 2 companies · 1 sharedFrederick M. Huds…Jack A. Khattar · 1 companies · 1 sharedJack A. KhattarJones W. Bryan, Ph.D. · 1 companies · 1 sharedJones W. Bryan, P…Michael B. Sheffery, Ph.D. · 1 companies · 1 sharedMichael B. Sheffe…Padmanabh P. Bhatt, Ph.D. · 1 companies · 1 sharedPadmanabh P. Bhat…Paolo P. Baroldi, M.D., Ph.D. · 1 companies · 1 sharedPaolo P. Baroldi,…Russell P. Wilson · 1 companies · 1 sharedRussell P. WilsonTami T. Martin, R.N., Esq. · 1 companies · 1 sharedTami T. Martin, R…William A. Nuerge · 1 companies · 1 sharedWilliam A. NuergeSupernus Pharmaceuticals Inc · $45.0M raisedSupernus Pharmaceutic…Michael James BighamMB
Michael James Bigham Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Michael James Bigham on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
John M. Siebert14
M. James Barrett, Ph.D.13
Frederick M. Hudson12
Charles W. Newhall III12
Paolo P. Baroldi, M.D., Ph.D.11
Jack A. Khattar11
Tami T. Martin, R.N., Esq.11
Russell P. Wilson11
Jones W. Bryan, Ph.D.11
William A. Nuerge11
Michael B. Sheffery, Ph.D.11
Padmanabh P. Bhatt, Ph.D.11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.